Cannabinoid Receptor 2 Blocking Peptide (#BLP-CR002) is the original antigen used for immunization during Anti-Cannabinoid Receptor 2 Antibody (#ACR-002) generation. The blocking peptide binds and ‘blocks’ Anti-Cannabinoid Receptor 2 primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
- Western blot analysis of rat RBL basophilic leukemia (lanes 1 and 3), rat C6 brain glioma (lanes 2 and 4) and rat lung (lanes 5 and 6) lysates:
- Western blot analysis of human THP-1 monocytic leukemia cell line lysates (lanes 1 and 4), mouse BV-2 microglia cell line lysates (lanes 2 and 5) and human Raji B lymphoblastoid cell line lysate (lanes 1 and 6):
- Expression of CB2 receptor in rat dermisImmunohistochemical staining of paraffin embedded section of rat dermis using Anti-Cannabinoid Receptor 2 Antibody (#ACR-002), (1:100). CB2 is expressed in sebaceous glands and ducts of sweat glands in the reticular dermis. Hematoxilin is used as the counterstain.
- Expression of Cannabinoid Receptor 2 in rat midbrain aqueduct.Immunohistochemical staining of perfusion-fixed frozen rat brain sections with Anti-Cannabinoid Receptor 2 Antibody (#ACR-002), (1:400), followed by goat anti-rabbit-AlexaFluor-488. A. CB2R immunoreactivity (green) appears in a layer lining the wall of the aqueduct (horizontal arrows) and astrocyte-like processes (vertical arrows). B. Pre-incubation of the antibody with Cannabinoid Receptor 2 Blocking Peptide (#BLP-CR002), suppressed staining. Cell nuclei are stained with DAPI (blue).
- (C)DRQVPGIARMRLDVR, corresponding to amino acid residues 228-242 of rat CB2 receptor (Accession Q9QZN9).